News & Updates

Aspirin for CRC prevention works better in presence of less healthy lifestyles

People with less healthy lifestyles appear to obtain greater protection against colorectal cancer (CRC) with aspirin use, according to a study.

Injection pain may predict postop pain outcomes

During induction of anaesthesia in gynaecological laparoscopic surgery, the incidence of propofol injection pain (PIP) and rocuronium‑induced withdrawal movement (RIWM) may predict the severity of postoperative pain and total opioid consumption, a prospective observational study has shown.

Cumulative BP load tied to incident CKD cases

High cumulative blood pressure (BP) loads appear to be associated with increased risk of chronic kidney disease (CKD), as reported in a prospective study.

Targeting PV source with ropeginterferon alfa-2b revolutionizes treatment

Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by overproduction of red blood cells, which poses a significant risk of thrombohaemorrhagic complications and impaired survival. Traditionally, treatment approaches have focused on managing the symptoms and reducing haematocrit levels, but these do not address the underlying cause of the disease.

Ropeginterferon alfa-2b (BESREMi, PharmaEssentia), an innovative monopegylated long-acting interferon, offers a novel approach by directly targeting and depleting JAK2-mutated hematopoietic stem cells (HSCs) in the bone marrow, which is the source of the disease. This article focuses on the role of ropeginterferon alfa-2b in transforming the treatment landscape for PV, its mechanisms, clinical benefits, and potential to significantly improve patient outcomes.